• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Dehydroeffusol Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5760293

Dehydroeffusol possesses anti-cancer, anxiolytic and sedative properties, it may antagonize the spasmogenic activity of various agents, and therefore, could be a promising agent in the treatment,of spasms. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Dehydroeffusol, Inhibitor
Full Product Name
Dehydroeffusol
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
250.3
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C17H14O2
SMILES
Cc(c1ccc(cc(cc2C=C)O)c2c1cc1)c1O
CAS Number
137319-34-7
Target & IC50
MMP
Antifection
ERK
In Vitro
In this study, we explored a novel anti-gastric cancer agent from a medicinal herb named Juncus effusus and found that the active component Dehydroeffusol (DHE), a small molecular phenanthrene, effectively inhibited gastric cancer cell proliferation and tumorigenesis by inducing tumor suppressive endoplasmic reticulum (ER) stress and by triggering moderate apoptosis. Mechanistic studies revealed that DHE selectively activated the intracellular tumor suppressive stress response by promoting the overexpression of the key ER stress marker DNA damage-inducible transcript 3 (DDIT3), through upregulation of activating transcription factor 4 (ATF4). Concurrently, DHE suppressed the expression of the cell survival and ER stress marker glucose regulated protein of molecular mass 78 (GRP78) via downregulation of the transcription factor ATF6. In addition, DHE markedly activated the stress response signaling pathway MEKK4-MKK3/6-p38-DDIT3, but significantly inhibited ERK signaling[1]

Product References and Citations for Dehydroeffusol, inhibitor

Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis. Biochem Pharmacol. 2016 Mar 15;104:8-18.
Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis. Biochem Pharmacol. 2016 Mar 15;104:8-18.
Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity. Toxicol Appl Pharmacol. 2015 Sep 1;287(2):98-110.
Effects of dehydroeffusol on spasmogen-induced contractile responses of rat intestinal smooth muscles.Planta Med. 2014 Aug;80(12):978-83.

Other Notes

Small volumes of Dehydroeffusol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Dehydroeffusol purchase

MBS5760293 is an inhibitor targeting Dehydroeffusol.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000